PCSK9 Inhibitors in Practice: Real-World Strategies for Cardiovascular Risk Reduction [Baltimore]
September 17, 2019
1425 Aliceanna St.
Baltimore, MD 21231
Tuesday, September 17, 2019
6:00 - 6:30 pm - Registration & Dinner
6:30 - 8:30 pm - Program
This symposium reviews current cardiovascular outcomes data for PCSK9 inhibitors, how to integrate non-statin lipid-lowering therapies and current cholesterol guidelines for the management of high CV-risk patients, and strategies for gaining access to PCSK9 inhibitors for high CV risk patients that need them.
In addition, attendees will have an opportunity to develop a treatment plan for real-world patients and compare and discuss their strategies with the faculty panel. Attendees are also encouraged to bring or submit difficult cases and questions to challenge the faculty in the “Stump the Faculty” segment.
This CME initiative will target Lipid Specialists, Cardiologists, Endocrinologists, Primary Care Providers (MDs/DOs), nurse practitioners (NPs), physician assistants (PAs), and other healthcare providers who practice in a primary care setting.
- Assess current cardiovascular outcomes data for PCSK9 inhibitors in patients at increased risk for CV events
- Integrate PCSK9 inhibitors in the management of real-world patients at high CV risk requiring additional LDL-C reduction
- Formulate strategies to improve patient access to PCSK9 inhibitors for those who require further CV risk reduction
Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email/mailing address and payment information). This information is confidential and will only be used to contact you regarding your registration.
Supporter Acknowledgment Statement
This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.
Tuesday, September 17, 2019
|6:00-6:30pm||Registration & Complimentary Dinner|
|6:30-6:35pm||Welcome & Pre-activity Assessment|
PCSK9 Inhibitors: A New Option for Reducing Cardiovascular Events in High-Risk Patients?
|6:50-7:50pm||Challenging Cases: What would you do?
Real-world patient cases for group case workshop – develop and discuss treatment plan with faculty panel
|7:50-8:20pm||Stump the Faculty: Controversies and Challenges in Lipid Management
Bring or submit your difficult cases and questions to challenge the faculty
|8:20-8:30pm||Post-activity Assessment & Adjourn|
Seth S. Martin, MD MHS FACC, FAHA, FASPC
Associate Professor of Medicine (Cardiology)
Johns Hopkins University School of Medicine
Dr. Martin is a core faculty member in the Ciccarone Center for the Prevention of Cardiovascular Disease and Director of the Advanced Lipid Disorders Center. Dr. Martin also serves as an Associate Faculty member in the Welch Center for Prevention, Epidemiology, and Clinical Research. He has a longstanding passion for preventive cardiology, in particular, cardiovascular risk assessment, lipidology, and mobile health technology. Dr. Martin has published more than 170 articles in leading cardiology and medicine journals, as well as 15 book chapters. He serves as Associate Editor for the American College of Cardiology’s Dyslipidemia Clinical Community and as an Associate Editor for the Journal of Clinical Lipidology.
Dr. Martin was selected as one of 125 faculty members, fellows, postdocs, staff and students who personify Johns Hopkins Medicine’s mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care, in celebration of the 125th Johns Hopkins Medicine anniversary.
Disclosure - Dr. Seth Martin has served on an Advisory Board for Amgen, Sanori and Regeneron.
Gregory Pokrywka MD FACP FNLA FASPC NCMP
Assistant Professor of General Internal Medicine
Johns Hopkins University School of Medicine
Gregory Pokrywka MD FACP FNLA FASPC NCMP is a Board-Certified Internist from Baltimore/Towson, Md. He attended Duke University, worked as a biochemist, attended University of Maryland Medical School and was Chief Resident in Internal Medicine at Mercy Hospital, Baltimore. He has been in private practice since 1987 and formed the Baltimore Lipid Center in 2001. Dr. Pokrywka has further pursued his interest in Menopausal Lipidology through certification as a Credentialed Menopause Practitioner by the North American Menopause Society (NAMS). He is a November 2005 Inaugural Diplomate of the American Board of Clinical Lipidology (“Board Certified in Clinical Lipidology”) and is one of a handful of U.S physicians double-certified in Menopause and Lipidology. In March of 2009 Dr. Pokrywka was elected by his peers to the honor of “Fellow of the National Lipid Assn.” (FNLA) Fellowship in the National Lipid Association recognizes the excellence, innovation, and leadership of health professionals in the NLA with respect to Clinical Lipidology in private practice or academic settings. Fellowship is reserved for NLA members who have made significant regional and/or national contributions to the science and practice of Clinical Lipidology. In August 2016 Dr. Pokrywka was among the first physicians elected by his peers as a Fellow of the American Society of Preventive Cardiology (ASPC). This honor recognizes excellence, innovation, and leadership in preventive
cardiology. Dr Pokrywka now serves as Assistant Professor for the Johns Hopkins University School of Medicine. In 11/2011 Dr Pokrywka completed a DATA 2000 compliant buprenorphine training program, and regularly treats opiate abuse patients, both in his own practice and as a Medical Director for First Step, and MATCinic, Baltimore. He has also participated in over 25 Clinical Trials with the IRC Clinical Research Center, and CPG Clinical Research of Towson, MD, as a Sub-Investigator and Principal Investigator, since 2012.
Dr. Pokrywka is a member of the American Heart Association Council on Atherosclerosis, the National Lipid Association (NLA), the International and the European Atherosclerosis Societies, the American Society of Preventive Cardiology, the Androgen Excess and PCOS Society, the Obesity Society, the Familial HyperCholesterolemia Foundation, the Lipoprotein(a) Foundation, and is a Fellow of the American College of Physicians. He participates enthusiastically in the Go Red for Women and WomenHeart campaigns to fight heart disease in women. He was elected to serve as a member of the Board of Directors of the Southeast Lipid Assn., 2009-2019, serves as NLA Regional Representative, and Vice-Chair of the NLA Membership Committee. Lecturing nationwide since 2001, Dr. Pokrywka has conducted since 2002 over 100 lipid / lipoprotein educational programs per year. He has lectured in 44 states to Internists/FP’s, Cardiologists, Ob/Gyns, Nurse Midwives, Physician’s Assts. and Nurse Practitioners at hospital and medical school grand rounds, CME programs, national tele- and web-conferences and multiple other venues on “Aggressive Detection and Prevention of ASCVD in Insulin Resistant Women” and “Women’s Menopausal Health.” Other areas of interest include “Advanced Lipoprotein Testing”, “Treatment of the Metabolic Syndrome”, “HDL Cholesterol”, “Diagnosis and Treatment of Hypertriglyceridemia”, “Cardiovascular Effects of Estrogen and Estrogen Receptor Modification”, “Diabetic Dyslipidemia”, PCOS and Cardiovascular Risk” and “Osteoporosis: Prevention and Treatment”. Dr. Pokrywka has served for years on the Editorial Board of the Journal of Clinical Lipidology, and was promoted to Associate Editor in 2017. In 2010 Dr. Pokrywka became the first NLA Fellow to offer both in-office Carotid IMT testing for the detection of subclinical atherosclerosis, as well as a CardioMetabolic Disease reduction / wellness program in partnership with Metagenics, Inc. (“FirstLine Therapy”) and Board Certified Clinical Nutritionists. Dr. Pokrywka serves on the National Lecture Bureaus of multiple pharmaceutical companies.
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Preventive CV Medicine, Lipidology and Hypertension
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, Northeast Chapter National Lipid Association
NYU Langone Medical Center LLC
New York, NY
Dr. Underberg is a Clinical Lipidologist. He is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of general internal medicine and endocrinology at NYU. Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and President of the National Lipid Association. He is a Fellow of the National Lipid Association, A Fellow of the American College of Physicians, A Fellow of the NY Academy of Medicine and Vice President of the American Board of Clinical Lipidology. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the National Lipid Association, the Foundation of the National Lipid Association, The American Society of Preventive Cardiology and the American Board of Clinical Lipidology. Dr. Underberg also serves on the scientific advisory board of the FH Foundation. Dr. Underberg’s Clinical Interests focus on the clinical management of patients with lipids and lipoprotein disorders and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of Clinical Lipidology.
Disclosure - Dr. Underberg has served on a Speakers Bureau for Amgen, Sanofi, Regeneron, Amarin, Akacea and Alexion. He has served as a Consultant for Amgen and Ambry and performed contracted research for Aegerion.
P. Barton Duell, MD
Dr. Duell’s special areas of interest include lipid disorders (e.g. high cholesterol), metabolic disorders, homocysteine metabolism, prevention of atherosclerosis (heart disease), diabetes, endocrinology and management of obesity. He currently serves as the director of OHSU’s Metabolic Disorders Clinic. He received his medical degree from OHSU in 1983, and completed his medicine residency at OHSU and the University of Chicago. He completed his metabolism, endocrinology and nutrition fellowship at the University of Washington in Seattle.
Disclosure - Dr. P. Barton Duell has served as a Consultant for Akcea, Astra Zeneca, Regeneron, Regenxbio, Esperion, and Retrophin. Institutional Grants were received from Regeneron, Regenxbio, Esperion and Retrophin.
Other Contributor/Planner Disclosures
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
How To Claim Credit
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the pre-test, post-test and activity evaluation
Statement of credit will be available to print from your user history page.